Inactive Instrument

Highlights SWEDISH ORPHAN BIOVITRUM London S.E.

Equities

0GY1

End-of-day quote London S.E. Other stock markets
- ^SEK	-

07-02	Sweden's Sobi Begins Rolling Application for Gout Treatment in US	MT
07-02	Sobi Initiates Rolling Biologics License Application to FDA for SEL-212 for the Potential Treatment of Chronic Refractory Gout	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Sweden's Sobi Begins Rolling Application for Gout Treatment in US	07-02	MT
Sobi Initiates Rolling Biologics License Application to FDA for SEL-212 for the Potential Treatment of Chronic Refractory Gout	07-02	CI
European Commission Grants Sobi® Marketing Authorisation for Altuvoct? for Treatment of Haemophilia A	06-19	CI
BerGenBio ASA Enter into A Clinical Trial Agreement with the Mays Cancer Center At the University of Texas Health Science Center At San Antonio and Swedish Orphan Biovitrum AB	05-28	CI
Sobi Finalizes Inaugural SEK3 Billion Bond Issue	05-08	MT
Sobi Secures Additional EU Indication for Rare Blood Disorder Therapy	05-08	MT
Sobi Wins EU Regulatory Panel's Positive Opinion for Hemophilia A Drug	04-26	MT
Sobi Receives Positive CHMP Opinion Recommending Approval of efanesoctocog alfa for Once-Weekly Treatment of Haemophilia A	04-26	CI
Sobi's SEK10 Billion Note Program Gets Regulatory Nod in Sweden	04-26	MT
Swedish Orphan Biovitrum AB Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Swedish Orphan Biovitrum AB Provides Earnings Guidance for 2024	04-25	CI
Sobi to Expand in South Korea via Rare Disease JV with Handok	02-13	MT
Orexo, Swedish Orphan Biovitrum to Further Explore AmorphOX Combination	02-12	MT
Orexo AB (Publ.) and Swedish Orphan Biovitrum AB (publ.) Agrees to Advance Feasibility Study with Amorphox	02-12	CI
Sobi's Growth Potential Remains 'Tremendous' Amid Conservative FY24 Outlook, RBC Says	02-09	MT
Swedish Orphan Biovitrum AB Provides Revenue Guidance for the Year 2024	02-08	CI
Swedish Orphan Biovitrum AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-08	CI
Swedish Orphan Biovitrum AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-08	CI
Sobi's Profit to Get Royalty Boost as Sanofi Partnerships Outperform, RBC Says	02-02	MT
Swedish Orphan Biovitrum Completes Issuance, Repurchase of Convertible Shares	11-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights SWEDISH ORPHAN BIOVITRUM London S.E.

Equities

0GY1

Highlights

Filters